CYTC - How High Can It Go! Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : CYTC - How High Can It Go!

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Tony J Brice who wrote ()	12/21/1999 10:37:00 PM
From: Jack Hartmann	of 185

Good article in 12/17/99 Valueline's selection and Opinion, page 5176 Some quotes of note: - Thin prep is rapidly taking market share from Pap smear - Earnings should mount rapidly - Clinical testing has established Cytyc's Thinprep system to be about 65% more effective than the customary Pap Smear - Physician find Thinprep far less time consuming and prefer it to the tedious traditional method - Given the payment approval of insurers, the potential domestic market for Thinprep may be on the order of 500 million a year - Company plans on spending 50 million to increase it market share from the present 15-20%. - "Even a modest gain in market sharefor Cytyc is likely to be enough to swell sales and earnings rapidly." - "Tripath is a potential rival, though several years behind Cytyc in terms of market development" - Cytyc spending $15M in R&D each year. Yep, I'm on board and ready to ride the train up. Just ask your local pathologist. Jack

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next